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Abstract 1	  
 2	  
Background: 3	  
Reductions in urinary protein excretion following Roux-en-Y gastric bypass (RYGB) surgery 4	  
in patients with diabetic kidney disease (DKD) have been reported in multiple studies.  5	  
Objectives: 6	  
To determine the weight loss dependence of the effect of RYGB on urinary protein excretion 7	  
by comparing renal outcomes in Zucker Diabetic Fatty rats (ZDF) undergoing either gastric 8	  
bypass surgery or sham operation with or without body weight matching.  9	  
Setting: 10	  
University laboratories. 11	  
Methods:  12	  
ZDF rats underwent surgery at 18 weeks of age. A sub-group of Sham operated rats were 13	  
body weight matched to RYGB operated rats by restricting food intake. Urinary protein 14	  
excretion was assessed at baseline and at post-operative weeks 4 and 12. Renal histology and 15	  
macrophage-associated inflammation were assessed at post-operative week 12.  16	  
Results: 17	  
Progressive urinary protein excretion was attenuated by both RYGB, and diet-induced weight 18	  
loss albeit to a lesser extent by the latter. Both weight loss interventions produced equivalent 19	  
reductions in glomerulomegaly, glomerulosclerosis and evidence of renal macrophage 20	  
infiltration  21	  
 22	  
4	  	  
Conclusion: 1	  
Weight loss per se improves renal structure and attenuates renal inflammatory responses in an 2	  
experimental animal model of DKD. Better glycemic control post-RYGB may in part explain 3	  
the greater reductions in urinary protein excretion following gastric bypass surgery. 4	  
Keywords: RYGB, gastric bypass, bariatric, diabetic kidney disease, weight loss, renal 5	  
inflammation, urinary protein excretion, Zucker Diabetic Fatty rat.  6	  7	  
5	  	  
 1	  
Introduction 2	  
 3	  
In the classical model of diabetic kidney disease (DKD) progression, incipient nephropathy 4	  
characterised by progressive microalbuminuria and initial hyperfiltration gives way over a 5	  
10-20 year period to overt urinary protein excretion and accelerated decline of renal function 6	  
as assessed by glomerular filtration rate (1). The progression of disease is associated with 7	  
renal inflammation and is driven by hypertension and hyperglycaemia. Despite increased use 8	  
of multimodal therapeutic regimens targeted at pharmacological remediation of these 9	  
vascular risk factors, DKD still often follows an inexorable course towards end stage renal 10	  
disease requiring dialysis or transplantation (2). 11	  
 12	  
Roux-en-Y gastric bypass (RYGB) is now increasingly considered as an option for treatment 13	  
of type 2 diabetes, in combination with medical therapy, in those patients not meeting 14	  
treatment targets or with diabetic complications (3, 4). Surgery is more effective than medical 15	  
therapy alone at inducing weight loss and improving glycaemic control (4). RYGB also 16	  
rapidly reduces urinary protein excretion in patients with type 2 diabetes (5, 6). This is 17	  
coincident with evidence of remediation of renal inflammation as measured by markers of 18	  
pro-inflammatory activity such as urinary monocyte-chemoattractant protein-1 (MCP-1) (5 6). 19	  
 20	  
Improvements in urinary protein excretion and renal inflammation correlate with the degree 21	  
of post-operative weight (5 6). Weight loss per se may therefore drive remediation of DKD. 22	  
Although a direct causal role for reductions in adiposity seems plausible, it remains 23	  
speculative in the absence of comparative studies examining the relative impact of matched 24	  
surgical and non-surgical weight loss. The relative importance of the weight loss component 25	  
of RYGB is challenging to test in clinical studies, as it is difficult to produce weight loss 26	  
equivalent to RYGB using a non-surgical treatment in humans (7).  27	  
6	  	  
 1	  
Using the Zucker Diabetic Fatty (ZDF) rat model of DKD (8) we recently demonstrated that a 2	  
12 week dietary restriction regimen tailored to deliver RYGB-equivalent weight loss reduced 3	  
total body weight in ZDF rats by approximately 20% relative to ad libitum fed rats (9). We 4	  
used this model in the present study to compare the relative impact of both RYGB and 5	  
equivalent weight loss achieved through caloric restriction on DKD in the ZDF rat (Figure 1). 6	  
 7	  
 8	  
Methods 9	  
 10	  
Animals 11	  
 12	  
ZDF rats are homozygous null mutant for the long isoform of the leptin receptor and develop 13	  
hyperphagia, progressive obesity, diabetes and renal microvascular complications (8). Ten-14	  
week-old male ZDF rats (fa/fa) (n=29) (Charles River Laboratories, France) and heterozygote 15	  
non-obese, non-diabetic healthy control ten-week-old ZDF rats (fa/+) (n=5) were group 16	  
housed in a temperature and humidity controlled room with a 12-hour light/dark cycle (lights 17	  
on from 02.00 to 14.00). Rats had free access to tap water and Purina Lab diet #5008 (Purina 18	  
Mills, St. Louis, MO) throughout the protocol, except where otherwise noted. All 19	  
experimental procedures were approved by the Veterinary Office of the Canton Zurich, 20	  
Switzerland and complied with national laws and current ethical guidelines.  21	  
 22	  
The surgical procedures have been previously described (9). Briefly, in the RYGB the jejunum 23	  
was dissected 60 mm distal from the ligament that attaches the jejunum to the colon 24	  
transversum. A 7-mm side-to side small bowel anastomosis was performed between the 25	  
biliopancreatic limb and the lower jejunum 250–300-mm proximal to the cecum to create the 26	  
common channel. After exposure and careful mobilization of the gastro-esophageal junction, 27	  
7	  	  
the stomach was transected just below the gastro-esophageal junction to create a small gastric 1	  
pouch about 2% of the original stomach size. The stomach remnant was subsequently closed, 2	  
and the small gastric pouch was anastomosed end-to-side to the alimentary limb, which was 3	  
∼500 mm in length. 4	  
 5	  
For the sham surgery, the entire gastrointestinal tract was mobilized and then a 10-mm 6	  
gastrotomy was performed on the anterior wall of the stomach with subsequent closure in two 7	  
layers. A 7-mm jejunotomy was then performed and subsequently closed. 8	  
 9	  
Glycaemic Control Monitoring 10	  
 11	  
Blood glucose was measured in all rats four times weekly with a point-of-care glucometer 12	  
(Breeze2, Bayer, Zurich, Switzerland). Using these values, a Glucose Area Under the Curve 13	  
(AUC) was calculated to evaluate glycaemic exposure over the course of the study. Urine 14	  
was collected over 24 hours in a metabolic cage during the week before surgery (-1 week) 15	  
and at 4 and 12 weeks post-operatively, respectively. Urine was stored at -20oC. 16	  
 17	  
Experimental Design (Figure 1) 18	  
 19	  
ZDF (fa/fa) rats were randomly assigned to RYGB (n=15), Sham surgery and ad libitum diet 20	  
(n=6), or Sham surgery and body weight matching (n=8). The RYGB group were not food 21	  
restricted. The Body Weight Matched group was food restricted to match the weight loss of 22	  
the RYGB group. Heterozygote controls (Non-obese Non-diabetic Controls, n=5) and the Ad 23	  
libitum Sham group were maintained on ad libitum diet. The Non-obese Non-diabetic 24	  
Controls did not receive any surgical or medical intervention.  25	  
 26	  
8	  	  
All animal work was conducted in line with the Guide for the care and use of laboratory 1	  
animals, Eighth edition (2011) under local ethics committee and national license approval. 2	  
During the twelfth post-operative week renal tissue was obtained at harvest and processed for 3	  
histology, immunohistochemistry and gene expression analyses.  4	  
 5	  
Histology & Immunohistochemistry 6	  
 7	  
Periodic Acid-Schiff (PAS) staining was performed on deparaffinised, rehydrated 4µM 8	  
paraffin-embedded renal sections using a commercially available PAS staining system and 9	  
protocol (395B-1KT, Sigma-Alrdich, Steinheim, Germany). 10	  
 11	  
Glomerular morphometry 12	  
 13	  
Using PAS stained slides, glomerular density was calculated as follows: glomerular density 14	  
(µM-2) = number of glomeruli captured/total cortical area analysed.  Glomerular cross 15	  
sections within these fields were then digitally traced at 40x and the mean glomerular cross-16	  
sectional area was calculated as follows: mean glomerular cross-sectional area = cumulative 17	  
cross-sectional area/number of glomeruli captured. 18	  
 19	  
Glomerulosclerosis 20	  
 21	  
In order to compare the observed frequency of glomerulosclerosis between groups, PAS-22	  
stained renal sections were semi-quantitatively assessed by digital light microscopy at 40x. 23	  
Briefly, partially (>25%) or completely sclerotic glomeruli within cortical fields were 24	  
counted, and the number of sclerotic glomeruli expressed as a percentage of the total number 25	  
of glomeruli assessed. Sclerosis was scored positively when mesangial expansion, increased 26	  
9	  	  
mesangial cellularity, adhesion formation, and capillary obliteration appeared present in at 1	  
least one segment accounting for >25% of the total glomerular cross-sectional area (10, 11). 2	  
 3	  
ED1 Immunohistochemistry 4	  
 5	  
Immunohistochemical analysis was performed on 4µM paraffin-embedded renal sections. 6	  
Slides were deparaffinised and rehydrated through xylene and alcohol. Endogenous 7	  
peroxidases were quenched using 5% H2O2 in citrate buffer for 15 minutes. Heat-mediated 8	  
antigen retrieval was performed in citrate buffer using a standard pressure pan for 15 minutes 9	  
followed by rapid cooling.  10	  
 11	  
The macrophage marker CD68 (ED1 antigen) was used to identify macrophages in renal 12	  
sections. Slides were incubated for one hour at room temperature in 1/50 mouse monoclonal 13	  
antibody to CD68 (ED-1, Ab31630, Abcam, Cambridge, United Kingdom), and rinsed 14	  
thoroughly with 0.05% Tween-20 in phosphate buffered saline (PBS). Negative controls were 15	  
performed by replacing the primary antibody with PBS. Secondary and tertiary antibodies 16	  
(polyclonal rabbit anti-mouse immunoglobulin/HRP [P0260] and polyclonal swine anti-17	  
rabbit immunoglobulin/HRP [P0217] 1/100 in 10% normal rat serum/PBS [090710, all Dako, 18	  
Glostrup, Denmark]) were then applied.  19	  
 20	  
Slides were then rinsed in PBS and visualised using diaminobenzidine (K3468, Dako, 21	  
Glostrup, Denmark) as a chromogenic substrate with a haematoxylin counterstain. A colour 22	  
deconvolution algorithm targeting DAB was used to quantify the area stained positive for 23	  
ED-1 within the captured cortical fields. This was expressed as a percentage of the total 24	  
analysis area, and the percentage area ED-1 positive was then compared between study 25	  
groups. Stained slides were digitally imaged using Aperio ScanScope (Leica Biosystems 26	  
Imaging, Nussloch, Germany) and analysed using Aperio ImageScope (Leica Biosystems 27	  
10	  	  
Imaging, Nussloch, Germany). All histomorphometric analyses were performed by a single 1	  
blinded investigator. For PAS and ED-1 stained slides consecutive rectangular cortical fields 2	  
containing at least 100 glomeruli in total were selected for analysis from each animal. 3	  
 4	  
Gene Expression Analyses 5	  
 6	  
RNA was isolated from snap frozen renal cortical tissue using Trizol Reagent (Qiagen, 7	  
Valencia, CA, USA). Following DNAse treatment and reverse transcription reactions 8	  
(Superscript® II, Life Technologies), TaqMan quantitative real-time polymerase chain 9	  
reactions were performed according to the manufacturer’s instructions, using primer sets for 10	  
CCL2 (MCP-1): Rn00566655_ml; available at: 11	  
https://www.lifetechnologies.com/us/en/home/life-science/pcr/real-time-pcr/real-time-pcr-12	  
assays/taqman-gene-expression.html; Life Technologies, Carlsbad, CA, USA). 18S was used 13	  
as an internal control and group data expressed as relative quantities using mean fa/+ group 14	  
values as an internal calibrator via the ΔΔCT method. 15	  
 16	  
Urinary Biochemistry 17	  
 18	  
Urinary creatinine and total protein were measured in samples of 24 hour urine collections on 19	  
an auto-analyser. A protein:creatinine ratio was then calculated as a normalised measure of 20	  
urinary protein excretion. Urinary MCP-1 was determined using the Rat MCP-1 Instant 21	  
ELISA kit (eBioscience; Vienna, Austria). 22	  
 23	  
Statistics 24	  
 25	  
11	  	  
All descriptive and inferential statistics were conducted using Prism (Graphpad Software, 1	  
California, U.S.A.). Data are presented as mean ± SEM. One-way ANOVA with post hoc 2	  
Bonferroni test was used to compare group data. Significance was set at p<0.05.  3	  
 4	  
 5	  
Results 6	  
 7	  
A total of 8 rats in the RYGB group died post-operatively, 4 in the immediate post-operative 8	  
period, and the remainder from 6 weeks post-operatively when they died of severe 9	  
hypoglycaemia. There was no mortality in the other groups. 10	  
 11	  
At baseline, all fa/fa rats (Ad libitum Sham, RYGB and Body Weight Matched) had 12	  
comparable protein:creatinine ratios, which were elevated 5-6 fold relative to the Non-obese 13	  
Non-diabetic Control group (p<0.05; Figure 2).  14	  
 15	  
As previously described, RYGB and Body Weight Matched rats achieved equivalent weight 16	  
loss, but plasma glucose levels did not improve among Body Weight Matched animals to the 17	  
same extent as RYGB rats. The Body Weight Matched group had greater plasma glucose 18	  
concentrations, with a cumulative post-operative glucose AUC of 1053mmol/L/day more 19	  
than the RYGB group (p<0.001) (9).  20	  
 21	  
There was a significant reduction in urinary protein excretion from baseline to week 4 post-22	  
RYGB (p=0.01) which was maintained to post-operative week 12. In the Body Weight 23	  
Matched group, there was an initial reduction in urinary protein excretion at post-operative 24	  
week 4 (p=0.02), although the absolute protein:creatinine ratio was on average 2-fold higher 25	  
than that observed in the RYGB group (p=0.009) at the same time-point. By post-operative 26	  
week 12, urinary protein excretion in the Body Weight Matched group increased but 27	  
12	  	  
remained reduced relative to the Ad libitum Sham group (p=0.04). No change in urinary 1	  
protein excretion from baseline to post-operative week 4 was seen in Ad libitum Sham rats 2	  
(age 21 weeks), but a significant 3-fold increase followed between post-operative weeks 4 3	  
and 12 (age 30 weeks) (p<0.01). 4	  
 5	  
Sclerotic lesions were reduced by 30-50% post--RYGB (p=0.01) and Body Weight Matched 6	  
(p=0.03; Figure 3A, 3B). The impact of RYGB and Body Weight Matched was similar 7	  
(p=0.34). Glomerular tuft size was increased on average by 39% in the Ad libitum Sham 8	  
versus the Non-obese Non-diabetic Control group (p<0.001, Figure 3C). No difference in tuft 9	  
size was observed between the RYGB and Body Weight Matched groups (p=0.17). The Ad 10	  
libitum Sham group showed evidence of DKD including focal sclerosis (arrow in Figure 3A 11	  
panel ii) and patchy tubulointerstitial inflammation. In 30% (+/- 3%) of glomeruli (Figure 12	  
2B) focal sclerosis occurred alongside tubular dilatation in the Ad libitum Sham group.  13	  
 14	  
Renal macrophage infiltration (Figure 4A and B), urinary MCP-1:creatinine ratio (Figure 4C) 15	  
and renal MCP-1 mRNA expression (Figure 4D) were all significantly attenuated by RYGB 16	  
and Body Weight Matching. There was no significant difference in effect between RYGB 17	  
and Body Weight Matching. Conversely, renal macrophage infiltration, urinary MCP-18	  
1:creatinine ratios and MCP-1 expression were all markedly elevated in the Ad libitum Sham 19	  
group relative to the Non-obese Non-diabetic Control, RYGB and Body Weight Matching 20	  
groups (all p<0.01.)  21	  
 22	  
 23	  
Discussion 24	  
 25	  
The present study set out to assess the relative impact of equivalent surgical (RYGB) and 26	  
non-surgical (dietary restriction in the Body Weight Matched group) weight loss on the 27	  
13	  	  
progression of DKD in the ZDF rat. The clinical relevance of the study stems from the 1	  
increasing use of surgical approaches such as RYGB as a means of correcting the diabetic 2	  
milieu and potentially arresting the onset or progression of complications of diabetes such as 3	  
DKD (4, 7, 12). 4	  
 5	  
There has been some concern regarding the use of bariatric surgery in kidney disease given 6	  
the potential for complications such as nephrolithiasis (13). However, the weight loss effect 7	  
may be of significant benefit. Unhealthy visceral fat stores have been directly implicated in 8	  
renal injury secondary to reduced production of renoprotective adipocytokines such as 9	  
adiponectin and simultaneous increases in the release of pro-inflammatory systemic signals 10	  
(14). Therefore a reduction in fat mass could concievably remediate the pro-inflammatory 11	  
activity contributing towards renal injury in DKD. Establishing whether weight loss per se, 12	  
when comparable in magnitude to that obtained following bariatric surgery, has a direct 13	  
impact on DKD outcomes constitutes an important question for translational bariatric 14	  
research in kidney disease.  15	  
 16	  
Diet-induced weight loss equivalent in magnitude to that obtained following RYGB is less 17	  
efficacious than surgery in reducing hyperglycaemia in the ZDF rat (9). Given the prevailing 18	  
idea that hyperglycaemia drives both renal inflammation and injury, we hypothesised that 19	  
equivalent weight loss without correction of hyperglycaemia would be less efficacious than 20	  
RYGB as a means of arresting DKD progression.  21	  
 22	  
Interestingly, significant weight loss achieved through dietary restriction in our Body Weight 23	  
Matched group had an equivalent impact on glomerular morphology and markers of renal 24	  
macrophage inflammation as compared to RYGB despite the persistence of hyperglycaemia. 25	  
Thus the present findings suggest that adiposity per se is a major driver of renal inflammation 26	  
and glomerulomegaly in DKD, and that weight loss is an important mediator of 27	  
14	  	  
improvements in DKD post-RYGB. This would suggest that weight loss alone could 1	  
remediate renal inflammation in DKD. 2	  
 3	  
Nonetheless, in the present study RYGB did produce superior improvements in urinary 4	  
protein excretion as compared with equivalent non-surgical weight loss. Given that there was 5	  
greater hyperglycemia in the Body Weight Matched group, one explanation may be that the 6	  
hyperglycemia itself promoted dysfunction at an ultrastructural level facilitating excess 7	  
urinary protein excretion. Electron microscopy based analysis of the glomerular filtration 8	  
barrier would have permitted further investigation of potential ultrastructural explanations for 9	  
these divergent results.  10	  
 11	  
Other inflammatory mediators may also be important at the filtration barrier. The effect of 12	  
inflammation at the level of the podocyte is incompletely understood. There is a negative 13	  
correlation between plasma adiponectin and kidney dysfunction in obese populations(15-17). 14	  
Adiponectin knockout mice have abnormal podocyte morphology(15). This altered 15	  
morphology is associated with functional deficits at the filtration barrier, and increased 16	  
urinary protein excretion. 17	  
 18	  
In a high fat fed rat model with strepozotozin induced diabetes, an extended RYGB can 19	  
enhance the expression of  anti-inflammatory factors  (18). This change is seen in parallel with 20	  
improvements in insulin sensitivity and reduced urinary protein excretion. RYGB specific 21	  
factors affecting metabolic control such as enhanced incretin responses may also contribute 22	  
to imrpovements in kidney disease (19). Some of the renoprotective effects of incretin 23	  
hormones such as glucagon-like peptide 1 have been shown to proceed independently of 24	  
hyperglycaemia in pre-clinical models (20).  25	  
 26	  
15	  	  
Therefore, there are multiple agents which are all likely to work in concert to produce 1	  
improvements in DKD following weight loss or RYGB. Our results suggest that weight loss 2	  
alone is sufficient to remediate renal inflammation, and can attenuate the progression of 3	  
urinary protein excretion. However, RYGB has a greater and more durable effect on reducing 4	  
urinary protein excretion in this study. The combination of enhanced glucagon-like-1 peptide 5	  
excretion, reduced hyperglycemia and improvements in the inflammatory millieu may 6	  
explain the greater effect of RYGB on urinary protein excretion. However, this remains 7	  
speculative at this point, and further translational work in human randomised clinical trials is  8	  
now needed to determine the role of bariatric surgery in the management of DKD.  9	  
 10	  
Conclusion 11	  
 12	  
Diet-induced weight loss equivalent to that achieved by RYGB can produce equivalent 13	  
reduction in renal inflammation in diabetic kidney disease. However, RYGB has a greater 14	  
effect on reducing urinary protein excretion. The greater effect of RYGB on glycaemic 15	  
control as compared to diet-induced weight loss may explain this discrepancy. To replicate 16	  
the beneficial effects of RYGB on DKD with non-surgical methods may thus require 17	  
combining intensified weight loss with pharmacological correction of hyperglycemia. 18	  
 19	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Figure Legends 2	  
 3	  
Figure 1-Experimental design 4	  
Homozygous Zucker Diabetic Fatty rats (ZDF-fa/fa) were allocated to RYGB (n=15) or sham 5	  
surgery comprising intestinal transection and re-anastomosis (n=14). In the sham surgery 6	  
group, rats were either allocated to dietary restriction to induce weight loss equivalent to the 7	  
RYGB group (Body Weight Matched, n=8) or allowed ad libitum access to food (Ad libitum 8	  
Sham, n=6). Heterozygous Fa/+ animals served as non-obese and non-diabetic controls 9	  
(n=5). Serial urine samples were collected 4 and 12 weeks after surgery prior to humane 10	  
euthanasia at the start of the 13th post-operative week. 11	  12	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Figure 2 Time dependent impact of RYGB or equivalent diet-induced weight loss (Body 3	  
Weight Matching) on urinary protein excretion in Zucker Diabetic Fatty rats 4	  
 5	  
Protein:creatinine ratios were measured in urine collections obtained  at 17 weeks of age (Wk 6	  
-1) 4 weeks post-operative (22 weeks of age) and one week before study close (Wk 12 weeks 7	  
post-operative, 30 weeks of age)   8	  
*p<0.05: RYGB Group 4 weeks Vs. Baseline **RYGB Group 12 weeks Vs. Baseline  9	  
+ p<0.05: Body Weight Matched Group 4 weeks Vs. Baseline 10	  
^p<0.05 RYGB versus BWM at 4 weeks 11	  12	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Figure 3 Time dependent impact of RYGB or equivalent diet-induced weight loss 3	  
(BWM) on urinary protein excretion and glomerular morphology in Zucker Diabetic 4	  
Fatty rats (fa/fa) 5	  
 6	  
A) Four micron thick coronal sections of kidneys from Zucker Diabetic Fatty rats and 7	  
heterozygote controls were stained with Periodic acid-Schiff and examined by medium power 8	  
light microscopy. Samples from each group are shown.  9	  
(i) Non-obese Non-diabetic Control (fa/+) animal showing normal PAS positivity,  10	  
(ii) focal glomerulosclerosis in the Ad libitum Sham group (arrow) 11	  
(iii) relatively structurally preserved glomeruli post-RYGB  12	  
(iv) relatively structurally preserved glomeruli after diet-induced weight loss  13	  
Scale bar=200µm 14	  
21	  	  
B) Percentage of sclerotic glomeruli per high powered field (HPF) and mean glomerular tuft 1	  
size  2	  
*p<0.05 Non-Diabetic Controls vs RYGB, Ab libitum Sham, and Body Weight Matched 3	  
groups.  4	  
+p<0.05 RYGB vs. Ad libitum Sham. 5	  
C) Tuft size is greatest in the Ad libitum Sham group and both RYGB and Body Weight 6	  
Matching move tuft sixe towards normal 7	  
*p<0.05 Non-Diabetic Controls vs Ab libitum Sham group.  8	  
+p<0.05 RYGB and Body Weight Matching vs. Ad libitum Sham. 9	  10	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Figure 4 Effect of RYGB and equivalent diet-induced weight loss (BWM) on renal 3	  
macrophage Infiltration and urinary and tissue MCP-1 levels in ZDF rats 4	  
 5	  
A) Four micron thick coronal section of kidneys from Zucker Diabetic Fatty (ZDF) rats and 6	  
heterozygote controls (fa/+) were stained for CD68 (ED1) to evaluate macrophage 7	  
infiltration. Examples from each group are shown at medium power magnification;   8	  
(i) non-diabetic fa/+ animals with no significant ED-1 staining 9	  
(ii) extensive peri-glomerular macrophage infiltration (brown stained areas) in an ALS 10	  
animal 11	  
(iii) reduced macrophage infiltration around the glomeruli post-RYGB  12	  
(iv) reduced macrophage infiltration around the glomeruli after diet-induced weight loss in 13	  
the BWM group  14	  
Scale bar = 200 µm 15	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B) The differences in ED1 area positivity as a percentage of cortical area was also calculated. 1	  
*p<0.05 ALS versus all other groups ).+p<0.05 versus ALS C) Urinary MCP-1:creatinine 2	  
ratios are compared at the final urinary collection of the study*p<0.05 ALS versus all other 3	  
groups ).+p<0.05 versus ALS at 12 weeks post-operatively (age 31 weeks) D). Relative 4	  
expression of MCP-1 mRNA was assessed in renal tissue *p<0.05 ALS versus all other 5	  
groups ).+p<0.05 versus ALS 6	  
 7	  
 8	   	  9	  
 10	  
 11	  
